Contrast - enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after
neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Symposium.